New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:09 EDTEGRXEagle Pharmaceuticals' licensor granted U.S. patent for dantrolene
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension. This patent issued expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012. Eagle is currently developing dantrolene in this new EHS indication. The company filed an NDA in January 2014 for Ryanodex in the treatment of Malignant Hyperthermia which was granted a priority review and has a PDUFA date of July 22, 2014. Ryanodex for the treatment of MH has also received Orphan Drug designation.
News For EGRX From The Last 14 Days
Check below for free stories on EGRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 12, 2014
10:49 EDTEGRXEagle Pharmaceuticals price target raised to $30 from $22 at Cantor
Cantor said Ryanodex, which Eagle Pharmaceuticals has priced significantly above the firm's initial expectations, is planned to launch at the end of this month and should help offset some of the losses associated with argatroban. The firm raised its price target on Eagle to $30 from $22 and reiterates its Buy rating on the shares.
August 11, 2014
07:33 EDTEGRXEagle Pharmaceuticals reports Q2 EPS (21c), consensus (37c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use